The Zhitong Finance App learned that China Biopharmaceuticals (01177) rose nearly 3%. As of press release, it had risen 2.32% to HK$5.29, with a turnover of HK$479.849 million.

According to the news, on October 14, China Biopharmaceutical announced that the results of a clinical study of the national Class 1 innovative drug TQ-A3334 (TLR7 agonist) independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), a subsidiary of the Group, have been selected for the latest breakthrough summary (LBA) of the 2026 American Society for Liver Disease Research (AASLD) annual meeting, and will be announced in the form of an oral report; Zhengda Tianqing and GlaxoSmithKline (GSK) strategic cooperation products Bepirovirsen (ASO) was selected for 2 oral presentations and 8 poster presentations (including 1 excellent poster).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.